stockrow
Friday 6 November 2026
Export VTRS’s income statement to Excel — free account
Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.
- Revenue
- −0.28%
- EPS
- −154.6%
- Free cash flow
- +38.8%
- Total debt
- −89.4%
Quarter to September 2026, against a year earlier
18.89
0.33
−1.72%
Follow VTRS
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.40 | 1.25 | 1.07 | 1.02 | |
P/FCF ratio |
10.03 | 9.77 | 9.07 | 7.52 | |
P/Operating CF |
22.92 | 48.38 | 40.20 | 17.87 | |
P/B ratio |
1.51 | 1.30 | 1.06 | 0.99 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.18 | 2.10 | 1.93 | 1.93 | |
EV/EBITDA |
11.84 | 11.39 | 9.55 | 9.01 | |
EV/Operating CF |
12.94 | 13.27 | 12.98 | 11.95 | |
EV/FCF |
15.65 | 16.36 | 16.35 | 14.27 | |
Quick Ratio |
0.74 | 0.63 | 0.72 | 0.61 | |
Current Ratio |
1.55 | 1.58 | 1.60 | 1.38 | |
Net Debt/EBITDA |
0.00 | 18.37 | 21.03 | 22.80 | |
Debt/Assets |
4.98% | 38.10% | 38.94% | 38.75% | |
Debt/Equity |
0.13 | 0.94 | 0.98 | 0.98 | |
Asset Turnover |
0.41 | 0.40 | 0.39 | 0.36 | |
Operating CF/Net income |
(2.76) | (3.21) | 2.20 | (2.40) | |
Capex/Depreciation |
0.00 | (0.07) | (0.18) | (0.23) | |
Interest Coverage |
2.33 | 0.05 | (0.66) | (1.61) | |
Research and Development Expense of Revenue |
0.00% | 6.61% | 7.07% | 7.42% | |
Selling, General and Administrative Expense of Revenue |
25.36% | 30.20% | 26.41% | 27.83% | |
Intangible Assets out of Total Assets |
0.57 | 0.58 | 0.57 | 0.59 | |
Share Based Compensation of Revenue |
1.06% | 1.03% | 1.37% | 1.33% | |
Graham Net Nets |
(0.52) | (0.58) | (0.72) | (0.87) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.99%) | (2.27%) | (1.95%) | (23.81%) | |
Free Cash Flow Yield |
9.97% | 10.23% | 11.03% | 13.30% | |
Revenue per Share |
0.00 | 3.23 | 3.04 | 3.16 | |
Operating CF per Share |
0.00 | 0.33 | 0.34 | 0.70 | |
Capex per Share |
0.00 | (0.04) | (0.10) | (0.15) | |
Free Cash Flow per Share |
0.00 | 0.29 | 0.23 | 0.55 | |
Cash per Share |
0.00 | 0.76 | 1.56 | 1.13 | |
Shareholders Equity per Share |
0.00 | 12.26 | 12.69 | 12.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 12.26 | 12.69 | 12.57 | |
Free Cash Flow |
896.50 | 336.20 | 268.00 | 640.40 | |
Working Capital |
3,661.30 | 3,709.90 | 4,106.50 | 2,694.90 | |
Capital Expenditures |
(2.90) | (45.60) | (120.30) | (175.40) | |
Net Current Asset Value |
(10,699.30) | (10,728.50) | (11,260.10) | (12,692.60) | |
EV/EBIT |
0.00 | 0.00 | 201.94 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.03 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 111.98 | 0.00 | |
| Other line items | |||||
Average Receivables |
3,246.40 | 3,192.15 | 3,101.00 | 3,126.30 | |
Average Payables |
1,723.35 | 1,754.55 | 1,868.90 | 1,803.90 | |
Average Inventory |
3,970.30 | 4,098.75 | 4,011.70 | 3,926.65 | |
Average Assets |
36,301.50 | 36,728.05 | 37,654.75 | 39,347.00 | |
Average Common Equity |
14,451.55 | 14,915.45 | 15,154.05 | 16,673.40 |
Columns are period end dates · fundamentals updated 5 Nov 2026